Analysis of inflammatory markers and platelet apoptosis markers during anticoagulant therapy in patients with COVID-19

Purpose of the study: to analyze the inflammatory markers MCP1, IP 10 and platelet apoptosis markers phosphatidylserine and calreticulin during anticoagulant therapy (ACT) in patients with COVID-19. Material and methods. The study included 370 patients. The patients were divided into 3 groups: group 1 - 190 people who received low molecular weight heparin (LMWH); Group 2 - 123 people taking unfractionated heparin (UFH); Group 3 - 57 people taking direct oral anticoagulants (DOACs). All patients upon admission and at the end of hospital treatment were assessed for general laboratory parameters, as well as the dynamics of specific markers of inflammation (IP-10 and MCP-1) and platelet apoptosis (phosphatidylserine and calreticulin) from July 2021 to January 2022.